nach oben

Drugs

Erschienen in:

01.08.2002 | Adis New Drug Profile

Fondaparinux Sodium

verfasst von: Susan J. Keam, Karen L. Goa

Erschienen in: Drugs | Ausgabe 11/2002

Einloggen, um Zugang zu erhalten

Abstract

▴ Fondaparinux sodium, a selective factor Xa inhibitor, is the first in a new class of antithrombotics. It binds selectively with high affinity to antithrombin III and specifically catalyses the inactivation of factor Xa. The elimination half-life of fondaparinux sodium permits once daily treatment.
▴ A randomised, double-blind, parallel-group, dose-ranging, multicentre phase IIb study in 933 eligible patients established that a subcutaneous dose of between 1.5 and 3mg of fondaparinux sodium has the optimum efficacy and safety profile for prophylaxis of venous thromboembolism in patients undergoing major orthopaedic surgery.
▴ Fondaparinux sodium, given to more than 3600 patients undergoing major orthopaedic surgery who participated in prospective, randomised, double-blind, multicentre phase III clinical trials, significantly reduced the incidence of venous thromboembolism, with an overall risk reduction of 55.2% compared with enoxaparin.
▴ Fondaparinux sodium was well tolerated by patients undergoing major orthopaedic surgery, and at the recommended clinical dose of 2.5mg has a similar tolerability profile, including bleeding events, to standard enoxaparin regimens. Fondaparinux sodium has not been reported to cause antibody-induced thrombocytopenia.

Turpie AGG, Gallus AS, Hoek JA, et al. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001 Mar 1; 344: 619–25PubMedCrossRef

Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119(1): 132S–75SPubMedCrossRef

Gallus AS. Applying risk assessment models in orthopaedic surgery: overview of our clinical experience. Blood Coagul Fibrinolysis 1999 Aug; 10 Suppl. 2: S53–61PubMed

Clagett GP, Anderson FA, Heit J, et al. Prevention of venous thromboembolism. Chest 1995 Oct; 108 Suppl. 4: 312S–34SPubMedCrossRef

Mohr DN, Silverstein MD, Ilstrup DM, et al. Venous thromboembolism associated with hip and knee arthroplasty: current prophylactic practices and outcomes. Mayo Clin Proc 1992; 67: 861–70PubMedCrossRef

Haake DA, Berkman SA. Venous thromboembolic disease after hip surgery: risk factors, prophylaxis and diagnosis. Clin Orthop 1989 May; 242(12): 212–31PubMed

Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopaedic surgery: review of epidemiology and economics. Am J Health Syst Pharm 2001; 58 Suppl 2: S4–13PubMed

Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997 Sep 4; 337: 688–98PubMedCrossRef

ten Cate JW. Evolution of therapies in deep vein thrombosis management. Blood Coagul Fibrinolysis 1999 Aug; 10 Suppl. 2: S5–S10PubMed

10.

Simpson JB. Deep vein thrombosis and total hip replacement surgery. Can J Hosp Pharm 1997 Feb; 50: 19–27

11.

Cohen AT. Applying risk assessment models in orthopaedic surgery: effective risk stratification. Blood Coagul Fibrinolysis 1999 Aug; 10 Suppl. 2: S63–70PubMed

12.

Aguilar D, Goldhaber SZ. Clinical uses of low-molecular-weight heparins. Chest 1999 May; 115: 1418–23PubMedCrossRef

13.

Boneu B. New antithrombotic agents for the prevention and treatment of deep vein thrombosis. Haemostasis 1996; 26 Suppl 4: 368–78PubMed

14.

Anon. Low molecular weight heparins first-line in DVT prevention. Drug Ther Perspect 1993 Apr 12; 1 (6): 1–4

15.

Diuguid DL. Choosing a parenteral anticoagulant agent. N Engl J Med 2001 Nov; 345(18): 1340–2PubMedCrossRef

16.

Porcari AR, Chi L, Leadley R. Recent advances in clinical trials of the direct and indirect selective factor Xa inhibitors. Expert Opin Invest Drugs 2000; 9(7): 1595–600CrossRef

17.

Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86(1): 1–36PubMedCrossRef

18.

Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15(1): 1–26CrossRef

19.

Lormeau JC, Hérault JP, Gaich C, et al. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107 A/ORG 31540 and of two structural analogues. Thromb Res 1997 Jan 1; 85(1): 67–75PubMedCrossRef

20.

Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997 May 23; 40(11): 1600–7PubMedCrossRef

21.

Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91(11): 4197–205PubMed

22.

Bendetowicz AV, Bara L, Samama MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res 1990; 58: 445–54PubMedCrossRef

23.

Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG-31540) with high affinity to antithrombin III in man. Thrombosis & Haemostasis 1995; 74(6): 1468–73

24.

Carrie D, Caranobe C, Saivin S, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY 216. Blood 1994; 84(8): 2571–7PubMed

25.

Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701: comparison with the ‘synthetic pentasaccharide’ (SR 90107/ORG 31540) and standard heparin. Circ Res 1996; 79(3): 590–600PubMedCrossRef

26.

Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparinplatelet factor 4 antibodies. Clin Appl Thromb Hemost 1999; 5(4): 259–66PubMedCrossRef

27.

Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8(2): 114–7PubMedCrossRef

28.

Pieters J, Willems G, Hemker HC, et al. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation. J Biol Chem 1988 Oct 25; 263(30): 15313–8PubMed

29.

Pieters J, Lindhout T, Willems G. Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralisation in plasma. Blood 1990 Aug 1; 76(3): 549–54PubMed

30.

Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor Vila-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 1996 Jul; 76(1): 5–8PubMed

31.

Gerotziafas GT, Bara L, Bloch MF, et al. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Blood Coagul Fibrinolysis 1998; 9(7): 571–80PubMedCrossRef

32.

Samama MM, Bara L, Walenga J. Comparative mechanism of action and pharmacokinetics of pentasaccharide and LMW heparins. 16th International Congress on Thrombosis; 2000 May 5–8; Porto, Portugal. 99–102

33.

Walenga JM, Fareed J. Relative contribution of factor Xa and factor IIa. Inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides. Thrombotic Haemorrhagic Dis 1991; 3(2): 53–9

34.

Walenga JM, Petitou M, Lormeau JC, et al. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187–98PubMedCrossRef

35.

Donat F, Duret JP, Santoni A, et al. Pharmacokinetics of Org31540/SR90107A in young and elderly healthy subjects: a highly favourable pharmacokinetic profile. The International Society on Thrombosis and Haemostasis (ISTH): XVIII Congress Supplement; 2001 July 6–12; Paris, France, P3094

36.

Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Montpellier, France: Sanofi Synthelabo, 2002; Data on file

37.

Paolucci F, Clavies M, Donat F, et al. In vitro binding of Org31540/SR90107A in human plasma and purified antithrombin III. The International Society of Thrombosis and Haemostasis (ISTH): XVIII Congress Supplement; 2001 July 6–12; Paris, France, P3095

38.

Faaij RA, Burggraaf J, Cohen AF. Lack of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the first synthetic factor Xa inhibitor and warfarin in human volunteers [abstract no. 234]. Blood 2000 Nov 16; 96, No. 11 (Part 1 of 2 Parts): 56a

39.

Donat F, Ollier C, Santoni A, et al. Safety and pharmacokinetics of coadministration of the first synthetic factor Xa inhibitor and aspirin in human subjects [abstract no. 226]. Blood 2000 Nov 16; 96, No. 11 (Part 1 of 2 Parts): 54a

40.

Burggraaff K, Faaij RA, Shoemaker RC, et al. Pentasaccharide (fondaparinux, Arixtra®) and the non-steroidal anti-inflammatory drug piroxicam do not interact in healthy subjects. Blood 2001; 98 (11 Pt. 2): 87b

41.

Turpie AGG, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002 May 18; 359: 1721–6PubMedCrossRef

42.

Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001 Nov; 345(18): 1298–304PubMedCrossRef

43.

Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001 Nov; 345(18): 1305–10PubMedCrossRef

44.

Lassen MR, Bauer KA, Erikssen BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002 May 18; 359: 1715–20PubMedCrossRef

45.

Turpie AGG. Overview of the clinical results of pentasaccharide in major orthopaedic surgery. Haematologica 2001; 86 (11 Suppl. II): 59–62PubMed

46.

Lassen MR, Turpie AG, Bauer KA, et al. Pentasaccharide versus enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: an overview of efficacy and safety results [online]. Available from URL: http://www.aaos.org/wordhtml/anmt2002/sciprog/296.htm [Accessed 2002 Feb 25]

47.

Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep-vein thrombosis [letter]. N Engl J Med 2001 Jul 26; 345(4): 291–2CrossRef

48.

Turpie AGG, Bauer KA, Eriksson BI, et al. Effect on efficacy and safety of the timing of the first pentasaccharide (fondaparinux, Arixtra®) administration in the prevention of venous thromboembolism (VTE) after major orthopaedic surgery [abstract no. 1119]. Blood 2001 Nov 16; 98 (11 Part 1)

49.

Rosenberg RD. Redesigning heparin. N Engl J Med 2001 Mar 1; 344(9): 673–5PubMedCrossRef

50.

Anon. Sanofi prepares pentasaccharide NDA for Nov. following favourable phase III. FDA Reports, The Pink Sheet 2000 Sep 11; 62 (37): 15–6

51.

Iqbal O, Silver P, Walenga JM, et al. Neutralization of the anticoagulant effect of a synthetic heparinomimetic (pentasaccharide) by heparinase 1: potential clinical implications. The International Society on Thrombosis and Haemostasis (ISTH): XVIII Congress Supplement; 2001 July 6–12; Paris, France, P2246

52.

Bijsterveld NR, Moons AHM, Boekholdt SM, et al. Neutralization of the anticoagulant effect of fondaparinux (Arixtra®) by recombinant activated factor VII in healthy male volunteers. 7th Congress of the European Association of Hospital Pharmacists 2002 Mar 20, Vienna, Austria.

53.

Anon. Organon/Sanofi Arixtra late January launch will be supported by 240 reps. FDA Reports, The Pink Sheet 2001 Dec 17; 63 (51): 3

54.

European Agency for the Evaluation of Medicinal Products (EMEA). Committee for proprietary medicinal products summary of opinion for Arixtra [online]. Available from URL: http://www.emea.eu.int [Accessed 2002 Feb 25]

55.

Anon. Sanofi-Synthelabo/Organon’s Arixtra launched in UK, its first European market. Pharma Marketletter 2002 Apr 8, 18

56.

Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/-ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation 2000 Nov 28; 102: 2726–31CrossRef

57.

Turpie AGG. The role in cardiology of the first synthetic factor Xa inhibitor: lessons from the results of the clinical programme in venous thromboembolism. The International Society on Thrombosis and Haemostasis (ISTH): XVIII Congress Supplement; 2001 6–12 July; Paris, France, SY112

58.

Sanofi Synthelabo. Pegasus newsletter. France: Sanofi Synthelabo, 2002 Apr; (Data on file)

59.

Sanofi Synthelabo. Personal communication: APOLLO study. 2002 May 25; (Data on file)

60.

Organon. Personal communication: ARTEMIS study. 2002 May 18; (Data on file)

61.

Coussement PK, Bassand J-P, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001 Sep; 22(18): 1716–24CrossRef

62.

Van de Werf F. New data in treatment of acute coronary syndromes. Am Heart J 2001 Aug; 142 (2 Suppl). S16–21PubMedCrossRef

63.

SoRelle R. Cardiovascular news (PENTUA study). Circulation 2001; 104: e9053PubMedCrossRef

64.

Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent — a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81(2): 214–20PubMed

Titel: Fondaparinux Sodium
verfasst von: Susan J. Keam
Karen L. Goa
Publikationsdatum: 01.08.2002
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2002
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200262110-00007

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2002

Cardiovascular Risk Profile of Antirheumatic Agents in Patients with Osteoarthritis and Rheumatoid Arthritis

Generalised Anxiety Disorder

Gene Therapy for Restenosis

Fondaparinux Sodium

Ocular Allergy Guidelines

Fondaparinux Sodium